{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"143-703-739-861-543","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"143-703-739-861-543","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10795,"type":"PATENT","title":"The Ohio State University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":7061,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8260,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"ohio state univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5396
Search Applicants and Owners separately: \"ohio state univ*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 5396
a) administering at least one anti-cancer treatment to a subject having a BCL2-associated cancer; and\n
b) administering at least one miR gene product selected from a miR-15a or miR-16-1 gene product; wherein the efficacy of the anti-cancer treatment is increased, and wherein the at least one miR gene product consists of a nucleotide sequence that is complementary to nucleotides 3741-3749 of SEQ ID NO:55."],"number":1,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the anti-cancer treatment is Chemotherapy."],"number":2,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the anti-cancer treatment is radiation therapy."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the BCL2-associated cancer is chronic lymphocytic leukemia (CLL)."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the BCL2-associated cancer is lymphoma."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 5, wherein the lymphoma is selected from the group consisting of follicular lymphoma, small cell lymphoma, large cell lymphoma, and non-Hodgkin's lymphoma."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein the BCL2-associated cancer is lung cancer."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 1, wherein an increase in the efficacy of an anti-cancer treatment is evidenced by increased remission of the cancer in the subject, relative to a suitable control."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A method of increasing the sensitivity of a BCL2-associated cancer cell to the cytotoxic effects of an anti-cancer agent, comprising administering to the BCL2-associated cancer cell at least one miR gene product comprising a miR-15a or miR-16-1 gene product, wherein the sensitivity of the cell to the anti-cancer agent is increased, and wherein the at least one miR gene product consists of a nucleotide sequence that is complementary to nucleotides 3741-3749 of SEQ ID NO:55."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the cancer cell displays increased expression of Bc12 protein relative to a control cell."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the cancer cell is present in a subject."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 11, wherein the subject is a human."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, further comprising administering the anti-cancer agent."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 13, wherein the at least one miR gene product and the anti-cancer agent are co-administered."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the cancer cell is selected from the group consisting of a CLL cell, a lung cancer cell and a lymphoma cell."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 15, wherein the cancer cell is a lymphoma cell selected from the group consisting of a follicular lymphoma cell, a small cell lymphoma cell, a large cell lymphoma cell and a non-Hodgkin's lymphoma cell."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the cancer cell is a lung cancer cell."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 17, wherein the lung cancer is a non-small cell lung carcinoma cell."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein the cancer cell is a cell that is associated with a cancer selected from the group consisting of acute myeloid leukemia, multiple myeloma, melanoma, a hematologic malignancy, a solid tumor, colorectal cancer, brain carcinoma, breast carcinoma, prostate carcinoma, Epstein-Barr virus-associated lymphoproliferative disease, renal carcinoma, hepatocellular carcinoma and gastric carcinoma."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 9, wherein an increase in the sensitivity of the cancer cell to the anti-cancer agent is evidenced by the death of the cancer cell."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["A method of inducing apoptosis in a cell comprising contacting the cell with at least one miR gene product comprising a miR-15a or miR-16-1 gene product, wherein the at least one miR gene product consists of a nucleotide sequence that is complementary to nucleotides 3741-3749 of SEQ ID NO:55."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, wherein the cell is a cancer cell."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the cancer cell displays increased expression of Bc12 protein relative to a control cell."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the cancer cell is selected from the group consisting of a CLL cell, a lung cancer cell and a lymphoma cell."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 24, wherein the cancer cell is a lymphoma cell selected from the group consisting of a follicular lymphoma cell, a small cell lymphoma cell, a large cell lymphoma cell and a non-Hodgkin's lymphoma cell."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 24, wherein the cancer cell is a lung cancer cell."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the lung cancer is a non-small cell lung carcinoma cell."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the cancer cell is a cell that is associated with a cancer selected from the group consisting of acute myeloid leukemia, multiple myeloma, melanoma, a hematologic malignancy, a solid tumor, colorectal cancer, brain carcinoma, breast carcinoma, prostate carcinoma, Epstein-Barr virus-associated lymphoproliferative disease, renal carcinoma, hepatocellular carcinoma and gastric carcinoma."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, wherein the cell is present in a subject."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 29, wherein the subject is a human."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating a cancer associated with overexpression of a BCL2 gene product in a subject, comprising administering an effective amount of at least one miR gene product comprising a miR-15a or miR-16-1 gene product, thereby treating the cancer, wherein the at least one miR gene product consists of a nucleotide sequence that is complementary to nucleotides 3741-3749 of SEQ ID NO:55."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the subject is a human."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the cancer is chronic lymphocytic leukemia (CLL)."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the cancer is lymphoma."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 34, wherein the lymphoma is selected from the group consisting of follicular lymphoma, large cell lymphoma and non-Hodgkin's lymphoma."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 31, wherein the cancer is lung cancer."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 36, wherein the lung cancer is non-small cell lung carcinoma."],"number":37,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}